ABSTRACT(Ϫ)-cis-1- piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111) is a novel human opiate receptor-like orphan receptor (ORL-1) antagonist that has high affinity for the clonal human ORL-1 receptor (hORL-1 K i ϭ 0.33 nM), selectivity versus -(174-fold), ␦-(6391-fold), and (486-fold)-opioid receptors and is able to inhibit nociceptin signaling via hORL-1 in a whole cell gene reporter assay. SB-612111 has no measurable antinociceptive effects in vivo in the mouse hot-plate test after intravenous administration but is able to antagonize the antimorphine action of nociceptin [ED 50 ϭ 0.69 mg/kg, 95% confidence limit (CL) ϭ 0.34 -1.21]. SB-62111 administration can also reverse tolerance to morphine in this model, established via repeated morphine administration. In addition, intravenous SB-612111 can antagonize nociceptin-induced thermal hyperalgesia in a dose-dependent manner (ED 50 ϭ 0.62 mg/kg i.v., 95% CL ϭ 0.22-1.89) and is effective per se at reversing thermal hyperalgesia in the rat carrageenan inflammatory pain model. These data show that an ORL-1 receptor antagonist may be a useful adjunct to chronic pain therapy with opioids and can be used to treat conditions in which thermal hyperalgesia is a significant component of the pain response.Nociceptin (orphanin FQ) is a 17-amino acid peptide identified as a potent endogenous agonist for the opiate receptorlike orphan receptor (ORL-1), a G protein-coupled receptor with a high degree of structural homology to the classical opioid receptors (Mollereau et al., 1994). Despite the high similarity in sequence between nociceptin and other opioid peptides, notably dynorphin A, nociceptin does not interact with -, ␦-, or -opioid receptors, and opioid peptides do not interact with the ORL-1 receptor (Meunier et al., 1995). Activation of the ORL-1 receptor with nociceptin can enhance cellular K ϩ conductance (Vaughan et al., 1997), inhibit Ca 2ϩ currents associated with N, L, and P/Q calcium channel activation (Knoflach et al., 1996;Connor and Christie, 1998), and block cellular cAMP production (Butour et al., 1997). These signaling mechanisms are represented in areas of the nervous system that are crucial for pain transmission, and nociceptin can act via these pathways to influence, for example, glutamate and GABA release in the periaqueductal gray (Vaughan et al., 1997) and neuronal activity in the dorsal root of the spinal cord (Lai et al., 1997). Furthermore, peptide antagonists of the ORL-1 receptor such as [N-Phe 1 ]nociceptin(1-13)NH 2 and UFP-101 have been shown to inhibit presynaptic 5-hydroxytryptaArticle, publication date, and citation information can be found at